In the Division of Infectious Diseases, the prominent clinician teachers and clinical scholars include: Drs. Paul Sax, James Maguire, Lindsey Baden, Cameron Ashbaugh, Francisco Marty, Sigal Yawetz, Florencia Pereyra, Rebeca Plank and Michael Klompas.
The clinical investigation, HIV, basic, and clinical studies group includes: Drs. Daniel Kuritzkes, Raphael Dolin, Paul Sax, Lindsey Baden, Francisco Marty, Manish Sagar, Rochelle Walensky, Florencia Pereyra, William Rodriguez, Sarah Hammond, Daniel Barouch, Anna Thorner, Shahin Lockman, Scott Peterson, Timothy Henrich, Athe Tsibris, Jonathan Li and Wendy Yeh.
The immunocompromised host and tuberculosis studies groups comprise Drs. Lindsey Baden, Francisco Marty, Nicolas Issa, Sarah Hammond, Sophia Koo, Wayne Marasco, and Deborah Hung.
The Global Health Equity and Social Medicine group includes Drs. Paul Farmer, Joia Mukherjee, Sonya Shin, Serena Koenig, Louise Ivers, Peter Drobac and Corrado Cancedda.
Drs. Elliott Kieff, Fred Wang, Karl Munger, and Kenneth Kaye of the viral oncology research group study Epstein-Barr virus, kaposi sarcoma, herpes virus and human papilloma virus-induced malignancies, including basic pathogenesis, immunology, and vaccine development.
Drs. Dennis Kasper, Matthew Waldor, and Miriam Barshak study basic and translational bacterial pathogenesis and vaccine development. Dr. James Maguire studies clinical pathogenesis of parasitic diseases.
We are very proud of all of the work by the members of our division. We would like to highlight a few of the more recent accomplishments that clearly demonstrate the important advances made in the field of infectious diseases, both in the clinical and research setting:
Expansion of the Global Travl Health Clinic at Brigham & Women's Hospital
First use of an oral formulation of RSV604 for RSV pneumonitis in transplant recipients.
Establishment of a new AIDS Clinical Trials Group (ACTG) site in Botswana, Africa.
2,400-person trial among HIV-1-infected mothers and infants in Botswana, Africa, evaluating approaches to prevent mother to child HIV-1 transmission.
Discovery that HIV-1-infected women who took single-dose nevirapine to prevent mother-to-child transmission of HIV-1 had good response to nevirapine-containing treatment, if they were able to start treatment six or more months postpartum, but that their response to treatment was worse (compared with the response among women without prior single dose nevirapine exposure) if they started treatment within six months of delivery
; results led to modifications of WHO HIV-1 treatment guidelines
Discovery that latency-associated nuclear antigen (LANA) directly binds the surface of the minimal chromatin unit, the nucleosome, to allow Kaposi’s sarcoma herpesvirus (KSHV) to persist in tumor cells;
this discovery provides a target for potential prevention and therapy of KSHV tumors.
Investigation of Modified Vaccinia Ankara vaccine in healthy volunteers with a post-vaccine Dryvax challenge
; this model defined with much detail the immune correlates for protection for the smallpox vaccine.
Derivation of a mutant Wyeth Vaccinia Virus strain for potential use in post-exposure prophylaxis.
Development of a rhesus model for studying the pathogenesis of Epstein-Barr Virus infection in primates using a molecular clone of the rhesus EBV.
Initiation of laboratory and clinical studies of adoptive molecular immunotherapy of human nasopharyngeal cancer, the principal EBV-associated malignancy.
Discovery that a CDK inhibitor affects the ability of EBV to maintain gene expression and episome persistence.
Identification of the DNA elements through which EBV effects c-myc expression and cell growth and critical proteins through which EBV increases cell survival.
Identification through synthetic lethal screens the genetic pathways necessary for HPV-infected cancer cell growth and survival.
Discovery that Alpha C protein of group B streptococcus binds to host cell glycosaminoglycan and mediates bacterial entry into host cells.
Characterization of a Drosophila model of Group B Streptococcal infection.
Development of a screen for inhibitors of Vaccinia Virus replication.
Report of the first characterization of a clinical HIV-1 isolate resistant to the CCR5 antagonist vicriviroc.
Use of ultra-deep pyrosequencing to characterize HIV-1 envelope sequence diversity and dynamic changes in the viral quasispecies in response to CCR5 antagonist therapy.
Development a platform for low-cost global health diagnostics, leading to three patents and the launch of a company that will bring the world’s first point-of-care CD4 cell counter to market.
Initiatition of a global health operations research program, in partnership with the Bill and Melinda Gates Foundation and the Clinton Foundation.
Send Feedback to: Jillian Arenz
This page was last modified on 2/23/2013